We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety of IFNa Kinoid in Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01058343
Recruitment Status : Completed
First Posted : January 28, 2010
Last Update Posted : March 21, 2019
Information provided by (Responsible Party):

Brief Summary:

Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be an attractive therapeutic strategy. Active immunization with IFNa kinoid (IFN-K) induces a polyclonal antibody response.

This study will evaluate the safety of IFN-K in patients with mild to moderate SLE. It will also measure the induction of anti-IFNa antibodies and evaluate the clinical impact on SLE disease.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Biological: IFN-K Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.
Study Start Date : March 2010
Actual Primary Completion Date : April 2011
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arm Intervention/treatment
Experimental: IFN-K 1
IFN kinoid dose 1
Biological: IFN-K
3 to 4 IM injections over 3 months

Experimental: IFN-K-2
IFN kinoid dose 2
Biological: IFN-K
3 to 4 IM injections over 3 months

Experimental: IFN-K 3
IFN kinoid dose 3
Biological: IFN-K
3 to 4 IM injections over 3 months

Experimental: IFN-K 4
IFN kinoid dose 4
Biological: IFN-K
3 to 4 IM injections over 3 months

Placebo Comparator: Saline
saline at same dose as IFN K
Biological: IFN-K
3 to 4 IM injections over 3 months

Primary Outcome Measures :
  1. Frequency and severity of adverse events [ Time Frame: study duration ]

Secondary Outcome Measures :
  1. Proportion of patients with anti IFNa antibodies [ Time Frame: Month 4 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria (4 of 11 ACR criteria),
  • 2. SLEDAI ≥4 and ≤10,
  • 3. Positive Anti-nuclear Antibodies (ANA) and/or Positive anti-dsDNA antibodies
  • 4. Male or female between 18 and 50 years of age
  • 5. Current immunity to measles, mumps, rubella and varicella, as evidenced by positive IgG titers at the time of screening,
  • 6. For subjects recruited during local influenza season, current vaccination against seasonal influenza at least 7 days prior to randomization,
  • 7. Vaccination against H1N1 influenza at least 7 days prior to randomization.
  • 8. For subjects with reproductive potential (males and females), use of a reliable means of contraception
  • 9. Written informed consent obtained from the subject.

Exclusion Criteria:

  • 1. Any serious manifestation of lupus at entry, that, in the opinion of the investigator is likely to require initiation of off-protocol medication changes during the course of the study and in particular no BILAG A score,
  • 2. Any non-SLE manifestation likely to require, in the investigator's judgment, treatment with high-dose corticosteroids or the addition of an immunosuppressive regimen during the course of the trial,
  • 3. Received > 20 mg/day of prednisone equivalent for > 7 days during the 30 days prior to screening,
  • 4. Currently receiving or having received pulse dose corticosteroids or intravenous immunoglobulin (IVIg) within 3 months prior to screening,
  • 5. Received cyclophosphamide within 3 months prior to screening,
  • 6. Received a monoclonal antibody during the 6 months prior to screening,
  • 7. Previously received an investigational treatment directed against IFNa,
  • 8. Received B-cell depleting therapy (e.g. Rituximab) within 12 months
  • 9. Received IV antibiotics during the 30 days prior to screening,
  • 10. Significant electrocardiogram (ECG) abnormalities ,
  • 11. Evidence of any clinically significant abnormality on a chest X-ray which, in the opinion of the investigator could represent active infection, latent tuberculosis or treatable manifestation of lupus,
  • 12. Any laboratory abnormality that is clinically relevant
  • 13. History of malignancy except completely excised basal cell carcinoma,
  • 14. Congenital immune deficiency,
  • 15. Positive IgM antibody titers in the presence of negative IgG titers to Epstein-Barr virus (EBV) or cytomegalovirus (CMV),
  • 16. Frequent recurrences of oral or genital herpes simplex lesions (≥ 6 / year),
  • 17. Episode of shingles within one year of screening,
  • 18. Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV) or HBV (HBsAg, anti-HBc ab) positive,
  • 19. Any current signs or symptoms of infection at entry,
  • 20. Administration of any live vaccine within the 3 months prior to study entry
  • 21. Planned use of any investigational or non-registered product

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01058343

Layout table for location information
Cliniques Universitaires St Luc
Brussels, Belgium
MHAT "Sveti Ivan Rilski"
Sofia, Bulgaria
University Hospital Split
Split, Croatia
KBC Zagreb
Zagreb, Croatia
Hopital Claude Huriez
Lille, France, 59037
Hopital Lapeyronie
Montpellier, France, 34295
Hopital de la Pitie Salpetriere
Paris, France
Hopital du Kremlin Bicetre
Paris, France
Hopital Haut-Leveque
Pessac, France
Kerckhoff-Klinik Gmbh
Bad-Nauheim, Germany
Berlin, Germany
Bern, Switzerland
Geneva University Hospital
Geneva, Switzerland, 1211
Geneva University Hospital
Geneva, Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Christian Jorgensen, MD, PhD Unité Clinique d'Immuno-Rhumatologie Thérapeutique, Hôpital Lapeyronie, Montpellier, France
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Neovacs
ClinicalTrials.gov Identifier: NCT01058343    
Other Study ID Numbers: IFN-K-001
First Posted: January 28, 2010    Key Record Dates
Last Update Posted: March 21, 2019
Last Verified: March 2019
Keywords provided by Neovacs:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases